Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
